Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil

Table 1 Sociodemographic and disease characteristics of patients at the index date

	CD patients (n = 118)	UC patients (n = 36)
Age (yr), mean ± SD	43.3 ± 12.6	44.9 ± 16.5
Female, n (%)	69 (58.5)	26 (72.2)
Employed, n (%)	36 (36.7)	5 (16.1)
Attended higher education, n (%)	32 (34.4)	5 (23.8)
Body mass index (kg/m2), mean ± SD	24.9 ± 4.7	24.9 ± 5.1
Current smokers, n (%)1	7 (5.9)	0 (0.0)
Family history of IBD, n (%)	15 (12.7)	2 (5.6)
IBD duration (yr), median (IQR)	11.0 (0.5-11.0)	6.5 (0.5-29.1)
Biologic group	11.0 (5.0-16.0)	6.0 (3.0-13.0)
Nonbiologic group	11.5 (4.5-18.5)	10.0 (4.0-17.0)
5-ASA derivates group	9.0 (4.0-13.0)	5.5 (4.0-14.0)
Non-5-ASA derivates group	11.5 (5.0-17.5)	13.0 (4.0-15.0)
Corticosteroid status, n (%)2
Steroid-dependent	17 (14.4)	10 (27.8)
Steroid-refractory disease	5 (4.2)	3 (8.3)
Not applicable (no previous use)	33 (28.0)	3 (8.3)
Unknown	37 (31.4)	15 (41.7)
Location of CD, n (%)
L1 ileal	26 (22.0)	-
L2 colonic	21 (17.8)	-
L3 ileocolonic	71 (60.2)	-
CD Behavior, n (%)
B1 nonstricturing/penetrating	31 (26.3)	-
B2 stricturing	52 (44.1)	-
B3 penetrating	35 (29.7)	-
Symptomatic perianal disease, n (%)	37 (31.6)	-
HBI result (available for 101 CD patients), median (IQR)	5.0 (1.0-9.0)	-
CDAI result (available for 43 CD patients), median (IQR)	200.0 (114.0-274.0)	-
Fecal calprotectin level > 200 µg/g during previous year, n (%)	40 (33.9)	-
Colonoscopy with CD activity 3 during previous year, n (%)	69 (58.5)	-
Extent of UC inflammation - Montreal classification, n (%)
E1 ulcerative proctitis	-	10 (27.8)
E2 left-sided UC	-	8 (22.2)
E3 pancolitis	-	18 (50.0)
Partial Mayo score, median (IQR)	-	6.0 (5.0-6.0)
Total Mayo score (available for 13 UC patients)	-	8.0 (7.0-8.0)
Extra intestinal manifestations4, n (%)	29 (24.6)	8 (22.2)
Patients with at least one IBD surgery during previous 3 yr, n (%)	32 (27.1)	1 (2.8)
Total colectomy	0 (0.0)	1 (2.8)
Fistulectomy	7 (5.9)	0 (0.0)
Enterostomy	6 (5.1)	0 (0.0)
Partial colectomy	5 (4.2)	0 (0.0)
Closure of enterostomy	5 (4.2)	0 (0.0)
Drainage of anorectal abscess	3 (2.5)	0 (0.0)
Jejunostomy/Ileostomy	1 (0.8)	0 (0.0)
Other	15 (12.7)	1 (2.8)
Patients with at least one IBD-related hospitalizations during previous 3 yr, n (%)	51 (43.1)	11 (30.6)

¹Smoking at Day 1 and has smoked 100 cigarettes in his/her lifetime.

²Steroid-dependent disease - defined as: (1) Being unable to reduce steroids below the equivalent of prednisolone at 10 mg/day within 3 mo of starting steroids, without recurrent disease; or (2) having a relapse within 3 mo of stopping glucocorticoids. Steroid-refractory disease - defined as having active disease despite prednisolone of up to 0.75 mg/kg/d over a period of 4 wk.

³As per investigator criteria.

⁴During the entire study period (3 retrospective years and 1 year of prospective follow-up), extraintestinal manifestations included arthralgia, arthritis, sacroiliitis, ankylosing spondylitis, erythema nodosum, pyoderma gangrenosum, pustular dermatitis, psoriasis, uveitis, sclerosing cholangitis, cholelithiasis, nephrolithiasis, autoimmune disease, hypertension, and dyslipidemia. SD: Standard deviation; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; HBI: Harvey-Bradshaw index; CDAI: Crohn’s disease activity index; pMayo: Partial Mayo score; 5-ASA: 5-aminosalicylate; IQR: Interquartile.